<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2008</study_start_year><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2061238</full_dataset_link><location>Greece</location><study_start_month>10</study_start_month><keyword>Second line</keyword><keyword>Irinotecan</keyword><keyword>Oxaliplatin</keyword><keyword>Leucovorin</keyword><keyword>Cetuximab</keyword><keyword>Metastatic colorectal cancer</keyword><keyword>Fluorouracil</keyword><keyword>Bevacizumab</keyword><repository>ECRIN MDR</repository><study_status>Terminated</study_status></additional><is_claimable>false</is_claimable><name>Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc</name><description>The aim of this study is to evaluate the efficacy of the effective drugs in a alternating chemotherapy schedules in pretreated patients with mCRC, who have received all effective drugs.</description><dates><creation>2008-10-15</creation></dates><accession>2061238</accession><cross_references><ClinicalTrials___gov>NCT00755118</ClinicalTrials___gov></cross_references></HashMap>